Merestinib

Drug Profile

Merestinib

Alternative Names: LY-2801653

Latest Information Update: 22 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Amides; Antineoplastics; Dihydropyridines; Pyrazoles; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Proto oncogene protein c met inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 03 Feb 2017 Phase-I clinical trials in Cancer (Late-stage disease, Metastatic disease) in Japan (PO) (NCT03027284)
  • 30 Jan 2017 Eli Lilly plans a phase I trial for Cancer (Late-stage disease, Metastatic disease) in Japan (PO) (NCT03027284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top